Abstract
Although the prognosis of adults with Philadelphia chromosome-negative acute lymphoblastic leukemia (ALL) has steadily improved over the past decade, less than 50% of patients maintain their remission at 5 years. Several approaches have been explored in the past few years including: monoclonal antibodies-either 'naked' (rituximab) or in combination with an immunotoxin (calicheamicin or maytansin), plant toxin (ricin), or bacterial toxin (Pseudomonas or diphtheria), and a novel bispecific T-cell-engaging antibody (blinatumomab); chimeric antigen therapy using autologous T cells that target CD19-expressing ALL; and novel agents such as proteasome inhibitors, liposomal vincristine, hypomethylating agents, nelarabine and NOTCH1 inhibitors. This review summarizes treatment approaches currently under investigation for the treatment of adult Philadelphia chromosome-negative ALL.
Original language | English (US) |
---|---|
Pages (from-to) | 2201-2212 |
Number of pages | 12 |
Journal | Future Oncology |
Volume | 10 |
Issue number | 14 |
DOIs | |
State | Published - Nov 1 2014 |
Keywords
- NOTCH1 inhibitors
- chimeric antigen receptor therapy
- immunotoxin
- novel monoclonal antibodies
- proteasome inhibitors
ASJC Scopus subject areas
- Oncology
- Cancer Research